. 2014 Feb 4;9(2):e87572. doi: 10.1371/journal.pone.0087572

Table 2. V2 sequences in V1V2-scaffold antigens tested with case-control specimens^*.

V1V2-scafffold Antigens	V2 Sequences
gp70.B(CaseA2)-V1V2.AP_orig	CSFNITTSIRDKVQKEYALFYK LDIVPI.DNPKNST.N.YRLISC
gp70.B(CaseA2)-V1V2.LL	CSFNITTSIRDKVQKEYALFYK LDIVPI.DNPKNST.N.YRLISC
gp70.C(97ZA012)-V1V2	CSFNTTTEIRDKKQQGYALFYR PDIVLLKENRNNSNNSEYILINC
gp70.AE(92TH023)-V1V2 ^‡	CSFNMTTELRDKKQKVHALFYK LDIVPIEDNTSSS.E.YRLINC
tags.C.(1086)-V1V2	CSFKATTELKDKKHKVHALFYK LDVVPL.NGNSSSSGE.YRLINC
gp70.A(92RW020)-V1V2	CSFNITTELKDKKQQVYSLFYK LDVVQINEKNET.D.K.YRLINC

Sequence of V2 residues present in the designated V1V2-scaffold antigens. Residues in bold indicate the V2 epitope recognized by RV144 vaccinees’ plasma as mapped with peptides [4]. Underlined residues represent the putative α4β7 binding site.

^‡

Sequence of V1V2 in ALVAC-HIV subtype E gp120 priming immunogen.

Table 2. V2 sequences in V1V2-scaffold antigens tested with case-control specimens*.

Table 2. V2 sequences in V1V2-scaffold antigens tested with case-control specimens^*.